Advanced Life Sciences Holdings, Inc. Share Price

Equities

ADLS

US00765H3057

Pharmaceuticals

Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for Advanced Life Sciences Holdings, Inc. -.--% -.--%
Sales 2009 2.79M 219M Sales 2010 753K 59.09M Capitalization 9.08M 712M
Net income 2009 -9M -706M Net income 2010 -9M -706M EV / Sales 2009 8.04 x
Net Debt 2009 9.16M 719M Net Debt 2010 7.94M 623M EV / Sales 2010 22.6 x
P/E ratio 2009
-1.05 x
P/E ratio 2010
-0.57 x
Employees -
Yield 2009 *
-
Yield 2010
-
Free-Float 84.42%
More Fundamentals * Assessed data
Dynamic Chart
Advanced Life Sciences Holdings, Inc. is a United States-based biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of drugs in the therapeutic areas of infection, cancer, and respiratory diseases. The Company’s Restanza is an antibiotic in development for the treatment of life-threatening infections including community-acquired bacterial pneumonia and biodefense pathogens including anthrax, plague, and tularemia. Its ALS-886 is a therapeutic molecule in preclinical studies is being developed for the treatment intended to reduce and prevent the tissue damage associated with diseases such as Adult Respiratory Distress Syndrome (ARDS). Its ALS-357 is a natural product in preclinical studies has demonstrated specific anti-tumor activity against malignant melanoma. Preclinical studies have shown that direct injection of ALS-357 into grafted human tumors induced apoptosis, programmed cell death, within the tumors.
More about the company